The Profile of Type 1 Leprosy Reaction at Leprosy Division of Dermatology and Venerology Outpatient Clinic of Dr. Soetomo General Academic Hospital, Surabaya, Indonesia
Downloads
Background: Leprosy is a chronic infectious disease caused by Mycobacterium leprae. Type 1 leprosy reaction is a delayed hypersensitivity reaction caused by the increased response of cellular-mediated immunity to the Mycobacterium leprae antigen on the skin and nerves with a reversal result. The clinical manifestation includes inflammation which can cause skin and nerve lesions, swell, to permanent disabilities. Purpose: To describe the demographic and clinical profile of type 1 leprosy reaction at the Leprosy Division of the Dermatology and Venerology Outpatient Clinic of Dr. Soetomo General Academic Hospital in 2017–2019. Methods: This was a descriptive study. We used secondary data from the medical records of leprosy patients at the Leprosy Division of Dermatology and Venereology outpatient clinic, Dr. Soetomo General Academic Hospital Surabaya, from January 2017 to December 2019. Result: Out of 364 patients, 65 (17.9%) had type 1 reactions. They were mostly in productive age at 35–55 years old (56.9%). The patients were predominantly male (75.4%), with normal nutritional status (98.5%) and negative bacterial index (72.3%). The most common types of leprosy were BB (Borderline) with 61.6% and BL (Borderline Lepromatous) with 20.8%. All patients took WHO (World Health Organization) MDT (Multi Drug Therapy) MB (Multi-Bacillary). Conclusion: The profile of type 1 leprosy reaction at the Leprosy Division of Dermatology and Venerology Outpatient Clinic of Dr. Soetomo General Academic Hospital in 2017–2019 shows an average data as follows: age 35–55 years, male, normal nutritional status, negative bacterial index, leprosy type BB.
Lastória JC, Abreu MAMM de. Leprosy: review of the epidemiological, clinical, and etiopathogenic aspects - part 1. An Bras Dermatol. 2014;89(2):205–18.
Peters RMH, Dadun, Lusli M, Miranda-Galarza B, van Brakel WH, Zweekhorst MBM, et al. The Meaning of Leprosy and Everyday Experiences: An Exploration in Cirebon, Indonesia. J.Trop.Med. 2013;2013:1–10.
Santé WHO= O mondiale de la. Global leprosy update, 2018: moving towards a leprosy-free world – Situation de la lèpre dans le monde, 2018: parvenir í un monde exempt de lèpre. Vol. 94, Weekly Epidemiological Record = Relevé épidémiologique hebdomadaire. World Health Organization = Organisation mondiale de la Santé; 2019. p. 389–411.
Kar HK, Kumar B. IAL textbook of leprosy [Internet]. New Delhi: Jaypee Brothers Medical Publishers; 2010 [cited 2021 Mar 10]. Available from: https://library.dctabudhabi.ae/sirsi/detail/342772
Nery JA da C, Bernardes Filho F, Quintanilha J, Machado AM, Oliveira S de SC, Sales AM. Understanding the type 1 reactional state for early diagnosis and treatment: a way to avoid disability in leprosy. An Bras Dermatol. 2013 Oct;88(5):787–92.
Suchonwanit P, Triamchaisri S, Wittayakornrerk S, Rattanakaemakorn P. Lepra reaction in Thai Population: A 20-Year Retrospective Study. Dermatol Res Pract. 2015;2015:1–5.
Raffe SF, Thapa M, Khadge S, Tamang K, Hagge D, Lockwood DNJ. Diagnosis and treatment of lepra reactions in integrated services--the patients' perspective in Nepal. PLoS Negl Trop Dis. 2013;7(3):e2089.
Aisyah I, Agusni I. A Retrospective Study: Profile of New Leprosy Patients. Periodical of Dermatology and Venereology. 2018;30:40–7.
Martelli CMT, Maroja M de F, Pardillo F, Stefani MMA, Villahermosa L, Scollard DM, et al. Risk Factors for Lepra reactions in Three Endemic Countries. AJTMH. 2015;92(1):108–14.
Motta A, Pereira K, Tarquinio D, Vieira M, Miyake K, Foss N. Lepra reactions: coinfections as a possible risk factor. Clinics. 2012;67(10):1145–8.
Cellona RV, Balagon MaVF, Gelber RH, Abalos RM. Reactions Following Completion of 1 and 2 Year Multidrug Therapy (MDT). AJTMH 2010;83(3):637–44.
Ranque B, Nguyen VT, Vu HT, Nguyen TH, Nguyen NB, Pham XK, et al. Age Is an Important Risk Factor for Onset and Sequelae of Reversal Reactions in Vietnamese Patients with Leprosy. Clin Infect Dis. 2007;44(1):33–40.
Thomas EA, Williams A, Jha N, Samuel CJ. A Study on Lepra Reactions from a Tertiary Care Center in North India. IJMRP. 2017;3(3):162–6.
Antunes DE, Ferreira GP, Nicchio MVC, Araujo S, Cunha ACR da, Gomes RR, et al. Number of lepra reactions during treatment: clinical correlations and laboratory diagnosis. Rev Soc Bras Med Trop. 2016;49(6):741–5.
Sarkar R, Pradhan S. Leprosy and women.IJWD. 2016;2(4):117–21.
Morey JN, Boggero IA, Scott AB, Segerstrom SC. Current directions in stress and human immune function. Curr Opin Psychol. 2015;5:13–7.
Rao PSS, John AS. Nutritional status of leprosy patients in India. Indian J Lepr. 2012;84(1):17–22.
Ribeiro de Jesus A. Micronutrientes que influyen en la resouesta inmune en la lepra. Nutricion Hospitalaria. 2014;(1):26–36.
Hungria EM, Oliveira RM, Penna GO, Aderaldo LC, Pontes MA de A, Cruz R, et al. Can baseline ML Flow test results predict lepra reactions? An investigation in a cohort of patients enrolled in the uniform multi-drug therapy clinical trial for leprosy patients in Brazil. Infect Dis Poverty. 2016;5(1):110.
Antunes DE, Araujo S, Ferreira GP, Cunha ACSR da, Costa AV da, Gonçalves MA, et al. Identification of clinical, epidemiological and laboratory risk factors for lepra reactions during and after multi-drug therapy. Mem Inst Oswaldo Cruz. 2013;108(7):901–8.
Brito M de F de M, Ximenes RAA, Gallo MEN, Bührer-Sékula S. Association between lepra reactions after treatment and bacterial load evaluated using anti PGL-I serology and bacilloscopy. Rev Soc Bras Med Trop. 2008;41 Suppl 2:67–72.
Sousa ALOM, Stefani MMA, Pereira GAS, Costa MB, Rebello PF, Gomes MK, et al. Mycobacterium leprae DNA associated with type 1 reactions in single lesion paucibacillary leprosy treated with single dose rifampin, ofloxacin, and minocycline. Am J Trop Med Hyg. 2007;77(5):829–33.
Fava VM, Manry J, Cobat A, Orlova M, Van Thuc N, Ba NN, et al. A Missense LRRK2 Variant Is a Risk Factor for Excessive Inflammatory Responses in Leprosy. Johnson C, editor. PLoS Negl Trop Dis. 2016 ;10(2):e0004412.
Fischer M. Leprosy - an overview of clinical features, diagnosis, and treatment: CME article. JDDG. 2017;15(8):801–27.
Spencer JS, Duthie MS, Geluk A, Balagon MF, Kim HJ, Wheat WH, et al. Identification of serological biomarkers of infection, disease progression and treatment efficacy for leprosy. Mem Inst Oswaldo Cruz. 2012;107(suppl 1):79–89.
Oertelt-Prigione S. Immunology and the menstrual cycle. Autoimmun Rev. 2012;11(6–7):A486-492.
Copyright (c) 2021 Berkala Ilmu Kesehatan Kulit dan Kelamin
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
- Copyright of the article is transferred to the journal, by the knowledge of the author, whilst the moral right of the publication belongs to the author.
- The legal formal aspect of journal publication accessibility refers to Creative Commons Atribusi-Non Commercial-Share alike (CC BY-NC-SA), (https://creativecommons.org/licenses/by-nc-sa/4.0/)
- The articles published in the journal are open access and can be used for non-commercial purposes. Other than the aims mentioned above, the editorial board is not responsible for copyright violation
The manuscript authentic and copyright statement submission can be downloaded ON THIS FORM.
